Ameritas Investment Partners’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
Other funds holding GALT
Ameritas Investment Partners's GALT Position: Q2 2026 in Review
Ameritas Investment Partners opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 4,349 shares worth $20.2K. The stake represents ﹤0.01% of the portfolio and ranks #2752 among its holdings. This is a return to the name: Ameritas Investment Partners previously reported a position in GALT as recently as Q1 2025.
Ameritas Investment Partners first reported a position in GALT in Q2 2019 and has held it in 13 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.
- Ameritas Investment Partners held 4,349 shares of Galectin Therapeutics worth $20.2K as of Q2 2026.
- Galectin Therapeutics was a new Ameritas Investment Partners position in Q2 2026.
- Galectin Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2752 holding.
- Ameritas Investment Partners first reported a position in Galectin Therapeutics in Q2 2019 and has held it in 13 quarters since.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.
Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.